Itraconazol Ab (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By preventing ergosterol formation, the drug disrupts the integrity of the fungal cell membrane, leading to impaired growth and eventual death of the organism.

The dosing regimen for Itraconazol Ab is individualized by the prescribing clinician based on the specific infection, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals determine the appropriate strength, frequency and duration.

Safety data for itraconazole in pregnancy and lactation are limited. The drug should be used only when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other azole antifungals, itraconazole offers a broad spectrum that includes many molds and dimorphic fungi. It has higher tissue penetration in skin, nails and some organs, but its drug‑interaction potential is greater than newer agents like voriconazole or posaconazole, requiring careful medication review.

Store Itraconazol Ab below 25 °C in its original packaging, protected from moisture and direct light. Do not expose the product to excessive heat or humidity, and keep it out of reach of children.

Itraconazol Ab is taken orally, usually with food to enhance absorption. The tablets or capsules should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events include hepatotoxicity, congestive heart failure, severe skin reactions such as Stevens‑Johnson syndrome, and visual disturbances. Patients should be monitored for signs of liver injury, fluid retention, rash or changes in vision, and therapy should be discontinued if these occur.

Itraconazol Ab is contraindicated in patients with known hypersensitivity to itraconazole or any azole component, those with uncontrolled heart failure, and individuals taking contraindicated medications such as rifampin or St. John’s wort. Caution is also advised for patients with severe hepatic impairment.